Orexin B: Unveiling the Precise Chemical Blueprint of a Key Neuropeptide
Background
Orexins (also known as hypocretins) are crucial neuropeptides produced in the hypothalamus, playing vital roles in regulating wakefulness, appetite, and energy homeostasis. Dysregulation of the orexin system is strongly implicated in severe conditions such as narcolepsy (characterized by excessive daytime sleepiness) and obesity. While the broad physiological functions of orexins are well-established, a precise and detailed understanding of Orexin B's specific molecular composition and structural characteristics is a foundational step required for advanced mechanistic studies and the rational design of targeted therapeutic agents.
Results
The PubChem profile for Orexin B (CID: 44404987) meticulously details its complex molecular architecture. Its precise molecular formula is C123H212N44O35S, indicating a remarkably large peptide composed of 123 carbon atoms, 212 hydrogen atoms, 44 nitrogen atoms, 35 oxygen atoms, and 1 sulfur atom. The molecular weight is precisely 2899.3 g/mol, confirming its substantial size and intricate amino acid sequence. This comprehensive chemical blueprint, including its extensive IUPAC name, is absolutely crucial for understanding its physical properties, predicting its biochemical behavior, and guiding its synthesis or modification in research settings. The most significant finding is the complete elucidation of Orexin B's molecular formula as C123H212N44O35S, providing the exact atomic composition of this vital neuropeptide.
Why It Matters
Understanding the exact chemical structure and properties of Orexin B is absolutely fundamental for advancing research into its biological roles and for rational drug design and development. This detailed molecular profile can directly guide the synthesis of specific analogues or mimetics that could selectively modulate orexin receptors (OX1R and OX2R). Such targeted compounds hold significant promise for potentially leading to novel therapies for a range of conditions, including chronic sleep disorders, metabolic dysregulation, and even addiction. Future steps critically involve leveraging this precise structural data for sophisticated in vitro and in vivo studies to thoroughly explore its pharmacological potential and develop lead compounds for clinical trials.